What question did this study set out to answer?

The study aims to evaluate the efficacy of TBL1XR1, MFAP5, and PSA as diagnostic biomarkers for prostate cancer.

February 13, 2026Open Access

Combination of serum TBL1XR1, MFAP5, and PSA as diagnostic biomarkers for prostate cancer

Key Points

The study aims to evaluate the efficacy of TBL1XR1, MFAP5, and PSA as diagnostic biomarkers for prostate cancer.
Evaluated serum levels of TBL1XR1, MFAP5, and PSA in individuals with suspected prostate cancer.
Analyzed the diagnostic accuracy of the combined biomarkers.
Compared the findings with traditional diagnostic methods.
The combination of TBL1XR1, MFAP5, and PSA significantly enhanced diagnostic accuracy for prostate cancer.
Using these combined biomarkers may lead to a reduction in unnecessary biopsies.
Serum levels of TBL1XR1 and MFAP5 were identified as promising indicators for prostate cancer.

Abstract

TBL1XR1 and MFAP5 have the potential for PCa diagnosis. The synergistic application of TBL1XR1, MFAP5, and PSA significantly enhances diagnostic accuracy. These findings indicate that serum TBL1XR1 and MFAP5 represent promising diagnostic markers for PCa. The combination of serum TBL1XR1 and MFAP5 with PSA for diagnosis may potentially reduce unnecessary biopsies in clinical practice.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Wu et al. (Thu,) studied this question.

synapsesocial.com/papers/698ebedd85a1ff6a93016266 https://doi.org/https://doi.org/10.1016/j.clinsp.2026.100868

Bookmark

View Full Paper